$24.49
Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Overview
52-week range
$5.55
$29
80% of range
Avg surprise (last 3)
+1.1%
Avg reaction (last 2)
+2.4%
50% positive
Latest IV / EM
102%
EM ±15.9% · $25 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.30 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-0.26 | $-0.30 | +13.3% | +3.7% | +9.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.44 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.30 | $-0.25 | -20.0% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.27 | $-0.30 | +10.0% | — | -4.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.24 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.26 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.25 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.37 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.38 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.27 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-7M | $-6M | — | $-8M | $-7M | $-6M | — | $-4M |
| Net income | $-7M | $-6M | — | $-7M | $-6M | $-5M | — | $-4M |
| EPS (diluted) | $-0.30 | $-0.26 | — | $-0.44 | $-0.30 | $-0.27 | — | $-0.24 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $22M | $25M | $32M | $35M | $27M | $30M | $19M | $17M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $22M | $25M | $32M | $36M | $27M | $30M | $19M | $17M |
| Total assets | $22M | $25M | $32M | $36M | $27M | $30M | $19M | $17M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $13M | $11M | $13M | $12M | $10M | $9M | $9M | $6M |
| Total equity | $9M | $14M | $18M | $24M | $17M | $21M | $10M | $11M |